Urocit-K®
Urocit-K is a wax-matrix controlled-release tablet containing the active substance potassium citrate.
Prescription only. This page provides marketing authorisation particulars.
This is a prescription medicinal product authorised in the name of Aymed İlaç Sanayi. The SmPC names it Urocit-K 10 mEq Controlled-Release Tablets; each tablet contains 10 mEq (1080 mg) of potassium citrate.
For information on the active substance, see What is potassium citrate?. The SmPC and patient leaflet contain the authoritative information on use.
- Product name
- Urocit-K 10 mEq Controlled-Release Tablets
- Product category
- Medicinal product for human use
- Active substance
- Potassium citrate
- Pharmaceutical form
- Controlled-release tablet
- Strength
- 10 mEq (1080 mg potassium citrate)
- Pack
- HDPE bottle of 100 tablets
- ATC code
- A12BA02
- Marketing authorisation number
- 2019/191
- Date of first authorisation
- 28.03.2019
- Marketing authorisation holder
- Aymed İlaç Sanayi
- Supply status
- Prescription only
Composition and pharmaceutical characteristics
The information below is taken from the composition, pharmaceutical form and pharmaceutical particulars sections of the Summary of Product Characteristics.
- Composition
- Each tablet contains 10 mEq (1080 mg) of potassium citrate.
- Description of pharmaceutical form
- Light yellow, oval, wax-matrix controlled-release tablet, marked “Mission” on the upper side and “610” on the underside. Length 20 mm; thickness 7 mm.
- Excipients
- Carnauba wax, magnesium stearate
- Shelf life
- 24 months
- Storage
- Store below 25 °C in a dry place.
Wax-matrix controlled-release technology
The tablet uses a controlled-release design in which the active substance is embedded in a wax-based matrix. The SmPC describes a wax-matrix controlled-release tablet and states that the matrix provides prolonged potassium release. The two excipients in the formulation are carnauba wax and magnesium stearate.
Product documents
The Summary of Product Characteristics (SmPC) is intended for healthcare professionals; the patient information leaflet provides information for patients. This website asks you to confirm that you are a healthcare professional before accessing the Urocit-K documents.
Translations are provided for information. The Turkish SmPC and patient leaflet contain the authoritative product information.
Frequently asked questions
Is Urocit-K prescription only?
Yes. Urocit-K is a medicinal product for human use and is supplied on prescription. A physician decides whether it should be used.
What type of tablet is Urocit-K?
According to the SmPC, it is a light yellow, oval, wax-matrix controlled-release tablet. Each tablet contains 10 mEq (1080 mg) of potassium citrate.
How many tablets are in a Urocit-K pack?
According to the SmPC, the product is supplied in an HDPE bottle containing 100 tablets.
How can I access the Urocit-K SmPC and patient leaflet?
The documents are in the Product documents section on this page. The SmPC is for healthcare professionals and the leaflet is for patients. Access on this website requires confirmation of healthcare professional status.
Who holds the marketing authorisation for Urocit-K?
The marketing authorisation holder is Aymed İlaç Sanayi. The authorisation number is 2019/191 and the date of first authorisation is 28.03.2019.
The particulars on this page are taken from the Summary of Product Characteristics; authoritative information is contained in the SmPC and patient leaflet. Consult your physician about your medicine and your pharmacist about its use. Other medicinal products from Aymed İlaç Sanayi are listed on the Prescription medicines page.